# Safety and Efficacy of Zoledronic Acid in Patients With Breast Cancer With Metastatic Bone Lesions

> **NCT00375427** · PHASE3 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 430 (actual)

## Conditions studied

- Breast Cancer With Bone Metastasis

## Interventions

- **DRUG:** Zoledronic acid

## Key facts

- **NCT ID:** NCT00375427
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-02
- **Primary completion:** 2010-02
- **Final completion:** —
- **Target enrollment:** 430 (ACTUAL)
- **Last updated:** 2012-04-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00375427

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00375427, "Safety and Efficacy of Zoledronic Acid in Patients With Breast Cancer With Metastatic Bone Lesions". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00375427. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*